Render Target: STATIC
Render Timestamp: 2024-11-01T10:24:05.911Z
Commit: 23cb9f61fe67e1e9093fd644a533c4ff516a6463
XML generation date: 2024-09-20 06:16:24.209
Product last modified at: 2024-10-17T12:00:28.913Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody (Alexa Fluor Conjugate)
PDP - Template ID: *******c8ce56b
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

GFAP (GA5) Mouse mAb (Alexa Fluor® 488 Conjugate) #3655

Filter:
  • IF
  • F

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Mouse IgG1 kappa
    Application Key:
    • IF-Immunofluorescence 
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Description

    This Cell Signaling Technology antibody is conjugated to Alexa Fluor® 488 fluorescent dye and tested in-house for direct immunofluorescence of rat cells. The unconjugated antibody GFAP (GA5) Mouse mAb #3670 reacts with human, mouse and rat GFAP protein. CST expects that GFAP (GA5) Mouse mAb (Alexa Fluor® 488 Conjugate) will also recognize GFAP in these species.

    Product Usage Information

    Application Dilution
    Immunofluorescence (Frozen) 1:400
    Flow Cytometry (Fixed/Permeabilized) 1:400

    Storage

    Supplied in PBS (pH 7.2), less than 0.1% sodium azide and 2 mg/ml BSA. Store at 4°C. Do not aliquot the antibody. Protect from light. Do not freeze.

    Protocol

    Specificity / Sensitivity

    GFAP (GA5) Mouse mAb (Alexa Fluor® 488 Conjugate) #3655 lacks sensitivity to detect GFAP in moderate-and low-expressing astrocytes, which can result in uneven staining patterns.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with native GFAP purified from pig spinal cord. The antibody was conjugated to Alexa Fluor® 488 under optimal conditions with an F/P ratio of 2-6.

    Background

    The cytoskeleton consists of three types of cytosolic fibers: microfilaments (actin filaments), intermediate filaments, and microtubules. Major types of intermediate filaments are specifically expressed in particular cell types: cytokeratins in epithelial cells, glial fibrillary acidic protein (GFAP) in glial cells, desmin in skeletal, visceral, and certain vascular smooth muscle cells, vimentin in cells of mesenchymal origin, and neurofilaments in neurons. GFAP and vimentin form intermediate filaments in astroglial cells and modulate their motility and shape (1). In particular, vimentin filaments are present at early developmental stages, while GFAP filaments are characteristic of differentiated and mature brain astrocytes. Thus, GFAP is commonly used as a marker for intracranial and intraspinal tumors arising from astrocytes (2). In addition, GFAP intermediate filaments are also present in nonmyelin-forming Schwann cells in the peripheral nervous system (3).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or [email protected].
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.